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Lymphopenia driven T cell activation is associated with autoimmunity. That lymphopenia does not
always lead to autoimmunity suggests that control mechanisms may exist. We assessed the importance
of the co-inhibitory receptor programmed death-1 (PD-1) in the control of lymphopenia-driven auto-
immunity in newly generated T cells vs. established peripheral T cells and in thymic selection. PD-1 was
not required for negative selection in the thymus or for maintenance of self tolerance following transfer
of established PD-1/ peripheral T cells to a lymphopenic host. In contrast, PD-1 was essential for
systemic self tolerance in newly generated T cells under lymphopenic conditions, as PD-1/ recent
thymic emigrants (RTE), generated after transfer of PD-1/ hematopoietic stem cell (HSC) precursors or
thymocytes into lymphopenic adult Rag/ recipients, induced a rapidly lethal multi-organ inﬂammatory
disease. Disease could be blocked by using lymph node deﬁcient recipients, indicating that lymphopenia
driven PD-1/ T cell activation required access to sufﬁcient lymph node stroma. These data suggested
that PD-1/ mice themselves might be substantially protected from autoimmunity because their T cell
repertoire is ﬁrst generated early in life, a period naturally deﬁcient in lymph node stroma. Consistent
with this idea, neonatal Rag/ recipients of PD-1/ HSC were resistant to disease. Thus, a critical role of
PD-1 resides in the control of RTE in lymphopenia. The data suggest that PD-1 and a paucity of lymphoid
stroma cooperate to control autoimmunity in newly generated T cells. Clinical therapies for autoimmune
disease employing lymphoablation and hematopoietic stem cell transplantation will need to take into
account functional polymorphisms in the PD-1 pathway, if the treatment is to ameliorate rather than
exacerbate autoimmunity.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The peripheral T cell compartment is tightly regulated by
homeostatic mechanisms. Reductions in T cell numbers, as occurs
in viral infections and lymphoablative therapy, can lead to a phys-
iological process called lymphopenia induced proliferation (LIP) [1].
There is evidence for several distinct forms of LIP, including a rapid
or acute proliferation (also called endogenous proliferation),
a slower IL-7 dependent ‘homeostatic’ proliferation, and a rapid
expansion of CD8 central memory cells that occurs in the presence
of excess IL-15. Both the slow [2e4] and rapid [5] forms of LIP5-126A Li Ka Shing Centre,
dmonton, Alberta T6G 2E1,
.
on).
-NC-ND license.demonstrate dependence on the presence of adequate lymph node
stroma, particularly in the case of CD4 LIP [2e4]. In contrast, the
form of LIP that leads to proliferation of central memory CD8T cells,
as occurs in lymphopenic mice lacking NK cells (e.g. IL-2Rg chain
deﬁcient [6,7]), occurs even inmice substantially deﬁcient in lymph
nodes [7].
Lymphopenia can exacerbate auto-reactivity of T cells by
homeostatic expansion [8,9]. However, syngeneic HSC or T cell
transfer into lymphopenic animals usually leads to LIP without
autoimmunity. Either mechanisms exist to prevent LIP-induced
autoimmunity or additional, as yet unknown, stimuli are required
to generate disease. Although the balance between multiple co-
stimulatory and co-inhibitory signals controls conventional T cell
responses [10], whether co-inhibitory signals control lymphope-
nia driven activation leading to autoimmune disease is unknown.
The PD-1 pathway is upregulated during viral infection [11] and
in a subset of T cells undergoing acute homeostatic proliferation
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activation. In addition, PD-1 deﬁciency leads to a narrow spec-
trum of late-life autoimmunity in mice [13e15] and human PD-1
polymorphisms [16] further support a role for PD-1 in self-
tolerance.
Control of homeostatic activation is likely to be particularly
important when the ﬁrst T cells seed the periphery during the fetal/
neonatal period [17,18]. Such newly generated T cells have not yet
had a chance to undergo peripheral tolerance, and therefore may
have greater autoimmune potential [19]. Consistent with an
increased need for control at this stage, recent thymic emigrants
(RTE) are considered to have a reduced ability to attain effector
function [20e22] despite having an increased capacity for LIP
[23e25]. Reduced effector function of RTE could be due to their
incomplete maturation [20,21] or instead an increased negative
regulation of fully competent cells. We examined these issues and
found that a high proportion of RTE express PD-1 and that PD-1
expression is necessary to prevent lymphopenia driven multi-
organ autoimmunity.2. Materials and methods
2.1. Mice
These studies used male and female B6.129S7-Rag1tm1mom/J
(abbreviated as Rag/), (C57BL/6J C57BL/10SgSnAi)-[KO]gc-[KO]
Rag2 knockout (abbreviated as Rag/ gc/), CD45.1-C57BL/6, TCR
transgenic Rag2/ Marilyn (originally obtained from the NIAID
Exchange Program) [26], and C57BL/6-Pdcd1/ (PD-1/; back-
crossed 11 generations to C57BL/6) mice originally generated by
Prof. T. Honjo and colleagues [14]. GFP Rag/, Rag/ Kb/ Db/,
and Rag/ PD-1/ mice were generated by crossing the above
Rag/ mice with C57BL/6-Tg(UBC-GFP) 30Scha/J, C57BL/6 H-
2Kbtm1-H-2Dbtm1N12 (from the NIAID Exchange Program, NIH:
004215) [27], and C57BL/6-Pdcd1/ mice respectively. C57BL/6-
HYcd4 (abbreviated as HYcd4) mice have been previously described
[28]. HYcd4PD-1/ mice were generated by crossing C57BL/
6-HYcd4 mice with C57BL/6-Pdcd1/ mice. Rag2/ Marilyn PD-
1/ mice were generated by crosses between Rag2/ Marilyn
with C57BL/6-Pdcd1/ mice. B6.129S2-Ltatm1Dch/J (abbreviated as
LTa/) were obtained from Jackson laboratory. Animal care was in
accordance with guidelines of the Canadian Council on Animal
Care.2.2. Stem cell transplantation
Fetal liver cells (day 15e16 fetuses) were used as a source of
hematopoietic stem cells (HSC) [29]. Six-eight week old immuno-
deﬁcient animals received 10e15106 fetal liver cells i.v. (from PD-
1/ or wild type (WT) fetuses). Recipients were not irradiated
unless indicated. In some experiments, as indicated, recipients
were given 15106 fetal liver cells containing a 1:1 mixture of PD-
1/ and WT CD45.1 cells.2.3. Deﬁnition of disease and histology
Disease included cachexia, hunched appearance, rufﬂed fur,
reduced mobility, skin and ocular lesions. Recipient mice were no
longer considered disease free when two or more of the above
symptoms were evident. Histological evaluations were completed
by a Veterinary Pathologist (R.R.E.U.) blinded to the treatment
groups.2.4. In vivo antibody treatment
We used a total dose of 1500 mg anti-mouse PD-1 mAb (J43),
anti-mouse PD-L1 (10F.9g2) and isotype control (Rat IgG2b) split
into six equal doses once every 5 days beginning at 30-35 days of
post WT HSC transplantation; timing of the start of injections was
determined by the detection of substantial T cell numbers in the
peripheral blood. NK cells in Rag/ mice were depleted by using
anti-mouse NK1.1 mAb (PK136) at a dose of 250 mg once per week
from dayminus 7 to day 28 relative to PD-1/HSC transplantation.
2.5. Flow cytometry analysis
Peripheral blood samples and splenocytes were stained after
incubation with an FcR block. T cell repertoire was analyzed by
using a Vb TCR screening panel (BD Pharmingen). A
FACSCalibur (BD Biosciences) with CellQuest Pro software and
BD LSR II (BD Biosciences) with FACS Diva software were used for
most of the data acquisition and analysis, with the exception of the
studies on HYcd4 mice. Analysis of HYcd4 thymocytes: Fluorochrome
conjugated antibodies for cell surface staining were purchased
from eBioscience. For intracellular cleaved caspase-3 staining, cells
were ﬁxed with the BD Cytoﬁx/Cytoperm Kit and then stained
with an anti-cleaved caspase 3 antibody purchased from Cell
Signaling Technology. Cell events were collected using a FACS Canto
II (BD Biosciences) and FlowJo software was used for data
analysis.
2.6. Irradiation bone marrow chimera experiments and adoptive
transfer studies
Rag/ gc / or GFP Rag/ recipients were lethally irradiated in
split doses (5 h apart) of a total of 9 to 12 Gy (Cesium source, Gamma
Cell 3000). A total of 107 bone marrow cells from GFP Rag/ or
Rag/ gc / donors were injected i.v. into Rag/ gc/ or GFP
Rag/ mice, respectively. Approximately two months post bone
marrow transplantation, recipients were given 15106 PD-1/
fetal liver cells. Thymocytes or splenocytes containing 5106 single
positive T cells from 7 week old PD-1/mice were injected i.v. into
immunodeﬁcient recipients. In experiments testing the adoptive
transfer of cells from diseased mice, splenocytes containing
3.5106 T cells from diseased or healthy mice were injected into
secondary Rag/ gc/ or Rag/ recipients. In other experiments,
WT or LTa/mice were lethally irradiated in split doses 48 h apart
to a total dose of 13 Gy. Immediately after the second split dose of
irradiation, all recipients were given 15106 PD-1/ or WT fetal
liver cells.
2.7. Adoptive transfer studies and FACS sorting
Thymocytes vs. splenocytes injected i.v. contained 5106 single
positive T cells from PD-1/ mice. To test transfer of disease,
splenocytes containing 3.5106 T cells from diseased or healthy
mice were injected into secondary recipients. TCRþ CD24lo cells
were sorted aseptically from splenocytes of ﬁve week old PD-1/
mice on a FACS BD inﬂux cell sorter (BD Biosciences). The purity
of the sorted cell populations was 92%.
2.8. BrdU incorporation, immunoﬂuorescence and serum cytokine
analysis
Experimental mice were treated with 2 mg BrdU in PBS by i.p.
injection. BrdU incorporation was assessed in splenic T cells after
36 h of injection using a BrdU ﬂow cytometry kit (BD
Pharmingen). For immunoﬂuorescence 5 mm cross-sections were
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rat anti-mouse CD4 or CD8a (Biolegend, San Deigo, CA) followed by
goat anti-rat Alexaﬂour 488 (Invitrogen Laboratories, Burlington,
ON) and visualized on a compound ﬂuorescent microscope (Axio-
plan, Axiovision 4.1 software, Carl Zeiss, Toronto, ON). Serum
cytokines were analyzed by multiplex bead immunassays (Bio-
Source-Invitrogen, Carlsbad, CA) using a Luminex 100 instru-
ment. Standard curves with deﬁned cytokine concentrations were
used to determine the concentrations of cytokines.
2.9. Statistical analysis
We used Prism version 4.0a (GraphPad Software Inc., SanDiego,
CA, USA) for statistical analysis. A student’s t-test (unpaired or
paired) and one-way analysis of variance (ANOVA) determined
statistically signiﬁcant differences (P< 0.05) between two and
three groups, respectively. The log-rank test was used to compare
survival curves. All data are expressed as mean SEM.Fig. 1. PD-1 is expressed on a high proportion of newly generated T cells. (A) Left: The frequ
and CD44hi and CD62Llo (effector memory) vs. CD62Lhi (central memory) cells. Right: The fr
TCRþ and CD24hi vs. CD24lo cells. (B, C) PD-1 expression on TCRþ gated cells from adult contr
WT HSC injection (HSC). (B) Representative analysis of T cells in the spleen. PD-1 staining of T
of PD-1þ T cells in the blood and spleen; mean and SE (Blood: HSC, n¼ 16; WT, n¼ 3; Spleen
1þ TCRþ cells that were either CD24hi vs. CD24lo at 40 or 180 days post HSC transplantatio3. Results
3.1. Requirement for PD-1 in RTE cells to prevent systemic
autoimmunity
PD-1 is expressed on an increased proportion of T cells with an
effector memory phenotype compared to a central memory
phenotype ([30], and Fig. 1A). To begin to examine if PD-1 may also
have a role in newly generated T cells, we examined PD-1 expres-
sion on CD24hi peripheral T cells, as CD24 is amarker of RTE [20,25].
A higher proportion of CD24hi T cells co-expressed PD-1 when
compared to CD24lo Tcells in four out of four wild type C57BL/6 (B6)
mice tested (P¼ 0.046; Fig.1A and Supplemental Fig.1). To examine
whether homeostatic activation of RTE might be under control of
PD-1, we transferred syngeneic B6 HSC into lymphocyte-deﬁcient
Rag/ recipients and examined PD-1 expression in the newly
generated T cells. We monitored the development of T cells by
checking their appearance in the peripheral blood of all HSCency of PD-1þ cells in splenic T cells from individual (n¼ 7) WT B6 mice gated on TCRþ
equency of PD-1þ cells in splenic T cells from individual (n¼ 4) WT B6 mice gated on
ol B6 mice (WT) and Rag/mice 50-56 days or day 40 and 180 (where indicated) post
CRþ gated spleen cells from PD-1/mice (ﬁlled grey) is also shown. (C) Left: Frequency
: d40, n¼ 7; d180, n¼ 4). Right: The frequency, in individual mice (n¼ 4), of splenic PD-
n.
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majority of the recipients, T cells were detected only after 30 days
post HSC injection (data not shown), as would be expected due to
the time required to establish the HSC in the bonemarrow followed
by subsequent migration of precursors to the thymus and the
ensuing maturation and selection processes. We found that PD-1
was expressed on a much higher proportion of T cells newly
generated fromHSC than on circulating or resident splenic T cells of
adult B6 mice (P¼ 0.009; Fig. 1B,C). Consistent with a key role for
PD-1 in RTE, the frequency of T cells expressing PD-1 declined
signiﬁcantly over time post HSC transplantation (day 40 vs. 180,
P¼ 0.014; Fig. 1C). In addition, a higher proportion of CD24hi T cells
co-expressed PD-1 when compared to CD24lo T cells in all HSC
recipients, both early and late post HSC transplantation (day 40,
P¼ 0.006; day 180, P¼ 0.002; Fig. 1C).
To test whether PD-1 was needed to prevent LIP-induced
autoimmunity in established T cells or speciﬁcally in RTE cells, we
transferred mature PD-1/ lymphocytes or their HSC precursors,
respectively, into Rag/ mice. Mature PD-1/ lymphocytes did
not induce any evident overt illness in lymphopenic animals
(Fig. 2A). In stark contrast, animals given PD-1/ HSC developed
lethal multi-organ disease (100% of animals; n¼ 60 frommore than
ten experiments) within several days to at most a few weeks post
appearance of T cells in the periphery, while, consistent with our
previous data [29], none of the animals given wild type (WT) HSC
developed disease (Fig. 2A). WT HSC could produce disease if the
recipients were treated with mAbs targeting PD-1 or PD-L1
(Fig. 2B). Consistent with the idea that RTE have a unique disease
inducing potential, PD-1/ thymocytes but not resident splenic T
cells could induce disease (Fig. 2A). Transfer of one million FACS
sorted TCRþ CD24lo splenic T cells from PD-1/ mice was also
unable to cause any overt disease when transferred into Rag/
mice (days of disease free survival: >100 4). On physical exami-
nation (Fig. 2C), diseased animals were not thrifty and were char-
acterized by cachexia, rufﬂed fur, scaly ulcerative skin and ocular
lesions (exudate and reddened conjunctiva). Diseased animals
showed lymphocytic inﬁltration in major organs such as the liver,
kidney, pancreas, heart, eye (Fig. 2C,E) as well as the lung and
esophagus (data not shown), and rapidly lost weight (Fig. 2D).
Inﬁltration in these tissues included CD4þ and CD8þ T cells in
recipients of PD-1/ but not WT HSC (one representative example
is shown in Fig. 2C). Cytokines play an important role in inﬂam-
mation and autoimmunity. A number of serum cytokine/chemo-
kines in PD-1/ HSC recipients were signiﬁcantly increased
compared to WT HSC recipients (Fig. 3A). Consistent with the
multi-organ nature of the disease, there was no obvious oligoclonal
expansion of T cells (Fig. 3B). Importantly, PD-1 and Rag double
knockout recipients of PD-1/ HSC (Fig. 3C) also developed
disease, showing that diseasewas not due to a response to potential
histocompatibility antigens linked to the Pdcd-1 locus.
In neonatal mice, previous studies suggested that CD8 T cells
trafﬁc into tissues where they encounter self tissue antigens pre-
sented by MHC class I on parenchymal cells and become tolerant
[31]. Should this trafﬁcking into tissue be defective in our model,
leading to a class I restricted autoimmunity within tissues, it would
predict that MHC class I deﬁcient recipients would be protected
from disease. To test this possibility we transferred PD-1/ HSC
into recipients lacking MHC class I (Rag/ Kb/ Db/) and found
that they were fully susceptible to disease (Fig. 3C). Thus, the
disease could not be explained by an inability of CD8 Tcells to trafﬁc
into adult tissues and become tolerant to MHC class I presented
antigens on parenchymal tissues. We conﬁrmed that disease is
indeed dependent on T cells by transferring PD-1/ HSC into
thymectomized Rag/ recipients. All successfully thymectomized
Rag/ recipients were free from disease (n¼ 4; days of disease freesurvival of >100 4), whereas euthymic Rag/ recipients devel-
oped disease (data not shown).
3.2. PD-1 deﬁciency does not prevent negative selection in the
thymus
The high frequency of PD-1 positive cells within RTE and the
lack of disease with established PD-1/ T cells suggested that PD-1
expression by RTE was required to control their function. However,
the autoimmunity caused by PD-1 deﬁcient RTE could also reﬂect
a requirement for PD-1 in negative selection in the thymus. While
some studies have suggested a role for PD-1 in positive selection
[32,33], data assessing PD-1 in negative selection have been limited
to the alloreactive 2C TCR transgenic model [14,34]. However, PD-1
expression has been observed on a subset of double positive (DP)
thymocytes undergoing negative selection using the physiological
HYcd4 model system suggesting that PD-1 signaling may be
important during deletional tolerance [35]. To examine the
contribution of PD-1 to thymic negative selection, HYcd4 PD-1/
mice were generated. There were no differences in the CD4 by CD8
proﬁles in male or female HYcd4 mice comparing PD-1/ mice to
their PD-1 expressing counterparts (Fig. 4A). Furthermore, there
was a similar reduction in the absolute number of T3.70þ DP and
CD8 single positive (SP8) thymocytes in HYcd4 male mice compared
to female mice regardless of PD-1 expression, indicating that
potentially auto-reactive thymocytes were being deleted similarly.
Equivalent negative selection in the absence of PD-1 was further
conﬁrmed by a similar increase in the activation of caspase-3 in
T3.70þ DP thymocytes from HYcd4 male mice compared to female
mice in the presence or absence of PD-1 (Fig. 4B). To evaluate the
effect of PD-1 deﬁciency on negative selection of CD4 T cells, we
generated Marilyn (anti-HY/I-Ab) [26] PD-1/ mice. Consistent
with the data on CD8 T cell selection, Marilyn thymocytes under-
went a similar level of negative selection in male mice in the
presence vs. absence of PD-1 (Fig. 4C,D). Taken together, these data
strongly suggest that the autoimmunity observed in the above
experiments is not the result of a defect in thymic negative selec-
tion when PD-1/ is absent during T cell development.
3.3. Control of lymphopenia driven activation and autoimmunity
through competition
Lymphopenia driven activation results from reduced competi-
tion for resources (MHC on dendritic cells and cytokines) that
occurs within lymphopenic lymph nodes, and can be blocked by
reducing lymph node stroma [5] or by increasing the number of
competitor T cells [1]; polyclonal naïve T cells compete with each
other to bind with self-MHC/peptide complexes and cytokines for
their survival and homeostatic proliferation [36]. Therefore, we
further tested our conclusion that PD-1 was needed to control
homeostatic activation of RTE cells by using two separate
approaches to increase the competition for resources. We used
hosts that have greatly reduced lymph node stroma when
compared to the adult Rag/ recipients and lymph node sufﬁcient
Rag/ hosts with added competitor T cells. To test whether disease
could be inhibited by provision of a competitor (bystander) T cell
population [3] we co-transfered WT stem cells with PD-1/ stem
cells. Since a hallmark of lymphopenia driven activation is the
conversion of naïve T cells into memory cells, we also examined in
these chimeras the frequency of PD-1/ T cells with a memory
phenotype. We found that 40% or more WT circulating T cells was
enough to reduce the frequency of effector memory phenotype T
cells (naïve and central memory T cell proportions increased) and
prevent disease development (Fig. 5A,B and supplementary
Table 1).
Fig. 2. Newly generated but not established PD-1/ T cells cause lethal multi-organ inﬂammatory disease in lymphopenia. (A) Adult Rag/ mice were given HSC from PD-1/ or
WT fetuses (n¼ 10 per group) or PD-1/ thymocytes or splenocytes (Thy or SP; n¼ 8e9 per group; both contained 5106 single positive T cells) and monitored for disease
incidence. The grey rectangle indicates the range, in days, at which the ﬁrst T cells were detected in the peripheral blood after HSC injection. (B) Adult Rag/ mice (n¼ 4e5) were
given WT HSC and treated with either anti-PD-1 or anti-PD-L1 beginning 30e35 days post HSC. (C) Top: Macroscopic pictures of representative recipients of PD-1/ and WT HSC.
Middle (six panels): Histology (hematoxylin and eosin staining; original magniﬁcation 100) of the liver, kidney and heart of recipients of PD-1/ (left) and WT (right) HSC. Arrows
point to areas of inﬁltration. Lower (four panels): Immunoﬂuorescence (original magniﬁcation 400) of pancreas from individual recipients of PD-1/ and WT HSC (similar data
were found for other organs). Blue: staining with the nuclear marker 40 ,60-diamidino-2-phenylindole (DAPI); green: CD4 or CD8 staining. (D) Body weight measurements in
individual recipients (n¼ 5) of PD-1/ or WT HSC. (E) Anterior uveitis and episcleritis were observed in recipients of PD-1/ HSC. Histology (H&E) of eyes from the recipients of
PD-1/ or WT HSC 45 days post HSC.
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Fig. 3. PD-1/ HSC cause increased circulating cytokines/chemokines without oligoclonal expansion and disease does not depend on host PD-1 or MHC class I. (A) Serum cytokines
were quantiﬁed from recipients of PD-1/ or WT (n¼ 4 per group) HSC (50 days post HSC). The serum cytokine concentrations of IFN-g, IL-13, TNF-a, IP-10, MIG, MCP-1, VEGF were
signiﬁcantly (P< 0.01) higher in PD-1/ than WT HSC recipients. Serum concentrations of IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17 were not signiﬁcantly (P> 0.05)
different between PD-1/ and WT HSC recipients (not shown). (B) CD4þ and CD8þ T cells from spleens of recipients of PD-1/ or WT HSC (n¼ 4 per group) were analyzed 50 days
post HSC for TCR diversity. (C) Left: Adult Rag/ PD-1/ (n¼ 4) mice were given PD-1/ HSC. Right: Adult Rag/ Kb/ Db/ (n¼ 4) mice were given PD-1/ HSC.
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the recipient’s lymphoid stroma rather than providing competitor T
cells. Two of the recipients with a relative deﬁciency in lymph node
stromawere the lymphotoxin deﬁcient (LTa/) mouse [37], which
lacks most secondary lymphoid tissue except spleen, and adult Rag
and common cytokine receptor gamma chain (gc) double knockout
recipients. Although LTa/ mice lack lymph nodes, they have
normal development of T cells and B cells. Rag/ gc/ mice lack
a functional IL-7R, substantially blocking lymph node development
[38]. Adult Rag/ gc/ recipients were completely resistant to
disease caused by PD-1/ HSC transfer (Fig. 5C), and lacked or had
reduced inﬁltration in major organs (Supplemental Fig. 2A). Lymph
nodes were generally absent in Rag/ gc/ recipients, and the few
lymph nodes that were found were greatly reduced in size
compared to Rag/ recipients, even 175 days after receipt of HSC(as expected [38]; data not shown). Lack of disease in Rag/ gc/
recipients suggested that inhibition of lymphopenia driven acti-
vation of RTE, due to a paucity of lymph node stroma, was domi-
nant over increased homeostatic activation that may result from
the loss of IL-7 mediated negative feedback on dendritic cells [39].
Lack of disease was not due to an inability to develop a functional T
cell response post HSC transfer to lymph node deﬁcient recipients,
as we have previously shown that such mice robustly reject even
well healed skin grafts [40]. In addition, lack of disease was not due
to a resistance of Rag/ gc/ tissues to immune attack; trans-
ferred splenocytes from diseased animals (PD-1/ HSC to Rag/
recipients) caused disease in both Rag/ and Rag/ gc/
secondary recipients (Fig. 5D and Supplemental Fig. 2B), consistent
with effector function and proliferation of memory T cells being
independent of lymphoid organs. In contrast, splenocytes from
Fig. 4. PD-1 deﬁciency does not impair negative selection. (A) Representative CD4 by CD8 proﬁles of T3.70þ thymocytes from HYcd4 female vs. male mice that are WT or PD-1/.
(B) Absolute numbers of T3.70þ of DP and SP8 thymocytes (Females, HYcd4 PD-1þ/þ: n¼ 15, HYcd4 PD-1/: n¼ 3, Males, HYcd4 PD-1þ/þ: n¼ 20, HYcd4 PD-1/: n¼ 6), top and
middle panels respectively. Bottom panel: Fold increase in percentage of cleaved caspase-3 T3.70þ DP thymocytes from indicated strain relative to percent cleaved caspase-3 DP
thymocytes from C57BL/6 mice (HYcd4F: n¼ 3, HYcd4F PD-1/: n¼ 5, HYcd4M: n¼ 4, HYcd4M PD-1/: n¼ 6). (C) Representative CD4 by CD8 proﬁles of TCR gated thymocytes from
Marilyn (Mar) female vs. male mice that are WT or PD-1/. (D) Absolute numbers of TCRþ of DP and SP4 thymocytes (Females, Mar PD-1þ/þ: n¼ 3, Mar PD-1/: n¼ 4, Males, Mar
PD-1þ/þ: n¼ 3, Mar PD-1/: n¼ 4).
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induce disease in either type of recipient (Fig. 5D). We next
examined markers of activation and proliferation in the Rag/ vs.
Rag/ gc/ recipients of WT vs. PD-1/ HSC. BrdU labeling
demonstrated that T cells of PD-1/ HSC recipients undergo much
more proliferation than recipients ofWTHSC (Fig. 5E). Rag/ gc/
recipients had signiﬁcantly lower numbers of splenic T cells, and
a lower frequency of memory phenotype and BrdU positive T cells
than Rag/ recipients (Fig. 5E). Remarkably, T cells of the Rag/
recipients of PD-1/ HSCwere almost universally effector memory
cells phenotypically, unlike Tcells of recipients ofWTHSC or Rag/
gc/ recipients of PD-1/ HSC (Fig. 5F).While disease resistance in Rag/ gc/ recipients was
consistent with a requirement for lymph node stroma in disease
induction, defects in innate immune cells of these recipients might
instead have prevented disease. For example, host NK cells might
be required for autoimmunity. To test these possibilities, we created
reciprocal bonemarrow chimeras between Rag/ and Rag/ gc/
recipients prior to transfer of PD-1/ HSC. Lack of disease was not
due to potential defects in Rag/ gc/ innate cells, as protection
from disease required gc deﬁciency in host radioresistant cells
rather than a deﬁciency of gc in the bone marrow cells (Fig. 6 and
Supplemental Fig. 3). The presence of disease in reciprocal bone
marrow chimeras did not correlate with the bone marrow’s
Fig. 5. Protection from lymphopenia driven activation and disease by WT competitor HSC or by using IL-2Rg deﬁcient recipients. (A) CD45.2 PD-1/ and CD45.1 WT HSC at a 1:1
ratio were given to adult Rag/mice (n¼ 13). Controls were given PD-1/ cells alone (n ¼ 3). (B) Top: Representative ﬂow cytometry gated on TCRbþ cells in blood from healthy vs.
diseased recipients of a mixture of CD45.2 PD-1/ þ CD45.1 WT HSC; 45 days post HSC. Bottom: Representative ﬂow cytometry (gated on TCRbþ CD45.2þ cells) in recipients of PD-
1/ plus WT HSC 45 days post HSC (See also supplementary Table 1). (C) Adult Rag/ gc/ mice (n¼ 7) or adult Rag/ (n¼ 5) mice were given PD-1/ HSC. Also see
Supplemental Fig. 2 for histology. (D) Disease incidence post adoptive transfer of splenocytes (SP) from diseased mice (PD-1/ HSC/ Rag/; abbreviated as Rag/ SP) or healthy
mice (PD-1/ HSC/ Rag/ gc/; abbreviated as Rag/ gc/ SP) into secondary Adult Rag/ gc/ (n¼ 3 per group) or Rag/ recipients (SP from diseased mice, n¼ 7; SP from
healthy mice, n¼ 4). Also see Supplemental Fig. 2 for histology. (E) Enumeration of splenic T cells and B cells in adult Rag/ recipients of PD-1/ or WT HSC and adult Rag/ gc/
recipients of PD-1/ HSC (splenic T cells in Rag/ recipients of PD-1/ were increased vs. WT HSC, n¼ 5, and vs. Rag/ gc/ recipients of PD-1/ HSC, n¼ 3, P< 0.01; splenic B
cells were signiﬁcantly lower, P< 0.05, than those of Rag/ recipients of WT HSC or Rag/ gc/ recipients of PD-1/ HSC). The percent BrdUþ T cells in spleen of Rag/
recipients of PD-1/ (n¼ 3) HSC was signiﬁcantly higher than that of Rag/ recipients of WT HSC (n¼ 3; P< 0.01) and Rag/ gc/ recipients of PD-1/ HSC (n¼ 3; P< 0.01)
examined 50 days post HSC. (F) Representative ﬂow cytometry showing the frequency of ‘memory’ T cells (gated on TCRbþ cells) in peripheral blood. The percent effector memory T
cells (CD44hi CD62Llo) in Rag/ recipients of PD-1/ HSC (n¼ 15; 92.28 0.83) was signiﬁcantly higher (P< 0.0001) than that of Rag/ recipients of WT HSC (n¼ 10; 58.35 6.8)
and Rag/ gc/ recipients of PD-1/ HSC (40.08 6.9) and Rag/ gc/ recipients of WT HSC (n¼ 3; 7.8 0.49), analyzed 40e50 days post HSC injection.
Fig. 6. Loss of host IL-2Rg-chain protects from disease; role of host hematopoietic cells
vs. radioresistant cells (A) Top: Experimental design for reciprocal bone marrow
chimeras used in B. Adult Rag/ gc/ (n¼ 6) or GFP Rag/ recipients (n¼ 7) were
lethally irradiated and given bone marrow cells from GFP Rag/ or Rag/ gc/ mice
respectively. 50 days later they were given PD-1/ HSC. See also Supplementary Fig. 3
for characterization of bone marrow chimeras by ﬂow cytometry. (B) Disease incidence
in bone marrow chimeras (see (A)) given PD-1/ HSC. (C) Failure of NK cell depletion
to prevent disease. Adult Rag/ recipients were treated with NK cell depleting anti-
body (PK136) and were given PD-1/ HSC (n¼ 4).
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had bone marrow capable of NK cell production and nevertheless
remained disease free, while Rag/ gc/ to GFP Rag/ chimeras
had bone marrow incapable of producing NK cells and yet rapidly
succumbed to disease. Furthermore, Rag/ recipients chronically
depleted of NK cells were also fully susceptible to disease (Fig. 6C).
Similar to the Rag/ gc/ recipients, disease was absent in
irradiated LTa/ recipients. In contrast, disease was present in
irradiated WT (LTaþ/þ) mice (Fig. 7A). Moreover, the frequency of
memory phenotype cells in irradiated LTaþ/þ recipients was
signiﬁcantly higher than those of irradiated LTa/ recipients
(Fig. 7B). Together these data indicated that reducing lymphoid
stroma could block disease, and suggested a possible explanation
for the paradox that PD-1 deﬁcient mice themselves do not
succumb to a rapidly lethal autoimmunity. The ability to prevent
disease by reducing lymphoid stroma, suggests that PD-1 deﬁcient
mice might be spared from strong autoimmunity because their T
cell repertoire is generated during the fetal/neonatal period when
lymphoid stroma is very limited. To test the role of recipient age, we
compared transfer of PD-1/ HSC into neonatal vs. adult Rag/
mice. Unlike adult recipients, nearly all of the neonatal recipients
remained disease free (Fig. 7C). The frequency of memory pheno-
type T cells was also greatly reduced in all of the neonatal recipients
that remained disease free (Fig. 7D). Taken together these data
strongly suggested that a systemic lack of tolerance with PD-1/
HSC occurred due to reduced competition and the presence of
adequate lymphoid tissue to support lymphopenia driven T cell
activation [3] of RTE.4. Discussion
Numerous co-inhibitory pathways have been identiﬁed and
while each may contribute to self-tolerance, their speciﬁc functions
are almost certainly unique [41]. Identiﬁcation of their unique
functions should provide more reﬁned strategies for tolerance
induction in autoimmunity and transplantation. Previous studies
have suggested a relatively limited role for PD-1 in self tolerance,with a deﬁciency in PD-1 signaling leading to tissue speciﬁc auto-
immunity, targeting a single tissue [15,42,43], or a variable late life
lupus like disease [14]. In the current study, we found that PD-1
deﬁciency can lead to a profound loss of self tolerance, leading to
rapid lethality associated with lymphocyte inﬁltration of many
organs. This widespread loss of self tolerance with PD-1 deﬁcient
cells, suggests that PD-1’s most critical function is in the control of
the autoimmune potential of newly generated T cells in the setting
of lymphopenia. We found no evidence for a reduced ability of PD-
1/ thymocytes, either those generatingMHC class I or II restricted
T cells, to undergo negative selection to conventional self peptide/
MHC complexes in the thymus. These data further emphasize that
control of tolerance by PD-1 is most likely to occur in the periphery.
Welsh and colleagues recently showed that PD-1 is highly
expressed on a subpopulation of established peripheral CD8 T cells
transferred into lymphopenic hosts, and was associated with
apoptosis and reduced their effector output [12]. They also sug-
gested that PD-1 may have a key role in preventing lymphopenia
driven autoimmune disease, although this hypothesis was not
examined. Some support for this hypothesis has come from recent
studies showing CD4 T cells in PD-L1 deﬁcient lymphopenic hosts
cause autoimmunity in the lung [43]. However, this relatively
limited autoimmunity was only demonstrated in the artiﬁcial
setting of a complete deﬁciency of Foxp3þ Treg cells (Foxp3
depleted cells), raising doubts about the physiologic signiﬁcance.
Our data indicated that PD-1 is critical to prevent a much more
generalized and rapid autoimmune disease induced by lympho-
penia, but that this function was critical for RTE rather than
established peripheral T cells. Importantly, the RTE generated
multi-organ autoimmunity we observed occurred without any
artiﬁcial depletion of speciﬁc cell populations such as Treg cells.
Together with the inability of established peripheral PD-1/ T cells
to cause the disease, the ability of thymocytes to cause disease and
the presence of a thymus dependent disease within several days of
the appearance of PD-1/ T cells in periphery post HSC trans-
plantation, indicated that RTE were responsible for disease. These
data also suggest that conﬁrmation of an intact PD-1 pathway may
be needed in the setting of lymphoablation and bone marrow
transplantation, particularly with autologous hematopoietic stem
cell transplants used to treat autoimmunity [44e47], where alter-
ations in this pathway can be expected.
Suggestive of a potential role for RTE in autoimmunity, a recent
report implicated RTE as a major component in the inﬁltrates of
human autoimmune thyroiditis [48]. Furthermore, studies showing
thymocytes or neonatal spleen cells but not adult spleen cells are
able to cause oophoritis and gastritis in lymphopenic mice [19] are
consistent with a greater autoimmune potential in RTE. RTE have
a particular importance in a number of settings where homeostatic
expansion can occur. RTE are critical to regeneration of the T cell
repertoire following lymphodepletion caused by viral infections or
intentionally generated by conditioning therapies used in hema-
topoietic stem cell transplantation. Thus, homeostatic activation of
RTE and the potential for autoimmunity to be triggered by immune
reconstitution post-lymphopenia have been major concerns.
However, these concerns have been tempered by observations
suggesting that RTE remain immature and deﬁcient in effector
function for a signiﬁcant period after migration into the periphery
[20e22]. We found that RTE are not functionally impotent but
instead harbor a heightened disease-inducing potential that is
under the control of negative regulatory pathways. It has also been
shown that the interactions between PD-1 and PD-L1 inﬂuences
CD8 T cells early after antigen encounter [49]. CD8 T cells rapidly up
regulated PD-1 expression upon encounter with antigen, when
antigen was expressed as neo-self antigen but not as a microbial
antigen. Blocking the PD-1/PD-L1 pathway with either anti-PD-1 or
Fig. 7. Resistance to disease and lymphopenia driven activation in adult LTa/ and neonatal Rag/ recipients. (A) Lethally irradiated LTaþ/þ (n¼ 8) or LTa/ (n¼ 5) mice were
given PD-1/ HSC. Controls were irradiated WT (n¼ 5) mice that were given WT HSC. (B) Representative ﬂow cytometry showing the frequency of ‘memory’ T cells (gated on
TCRbþ cells) in peripheral blood of mice shown in A. The frequency of CD44hi CD62Llo T cells in LTaþ/þ (n¼ 8; 41.8 4.5) recipients of PD-1/ HSC was signiﬁcantly higher (P< 0.01)
than that of LTa/ recipients (n¼ 5; 12.3 3.1) or control (n¼ 5; 7.0 0.45) recipients that were given WT HSC. (C) Day 1 Rag/ neonates (n¼ 7) or adult Rag/ (n¼ 7) mice were
given PD-1/ HSC and development of disease monitored. (D) The percent CD44hi CD62Llo T cells in neonates (n¼ 7; 30.8 5.7) was signiﬁcantly lower (P< 0.0001) than that of
adult recipients (n¼ 7; 89.51.5) analyzed 40e50 days post PD-1/ HSC.
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encounter prevented tolerance [49,50]. Thus, PD-1 may have an
important role in controlling the early T cell response to self-
antigen and in the response to homeostatic signals in RTE.
Our data, showing that approximately 95% of T cells phenotyp-
ically become effector memory cells when they lack PD-1 and go
through the RTE stage in a lymphopenic host, strongly suggests that
the disease is driven in a polyclonal fashion. The autoimmunitymay
in addition require autoantigen recognition, a question that could
be addressed using the elegant approach employed recently for
disease due to CTLA-4 deﬁciency [51]. Furthermore, the ability to
inhibit disease with competitor HSC or by reduction of lymphoid
stroma is associated with greatly reduced polyclonal activation.
Mechanistically, the lack of PD-1 in LIP might have changed the
Treg:Teffector ratio by increasing Teffectors or because of a reduced
ability to generate induced Treg cells [43,52], a possibility we are
investigating.
Homeostatic activation is conventionally considered to be acti-
vation resulting from reduced competition for resources (binding
to self MHC, cytokines from APCs/Stroma etc.) [53]. However, the
lack of autoimmunity and LIP in Rag/ gc/ recipients of PD-1/
HSC initially seemed surprising given that previous studies have
shown CD8 T cells can have enhanced LIP in gc/ recipients [6,7];
enhanced LIP was attributed to the lack of NK cells in these mice
and hence reduced competition for IL-15 between pre-existing
central memory CD8 cells and NK cells [7]. However, our studies
speciﬁcally assessed the requirement for gc in autoimmunity and
LIP of newly generated T cells (lacking any pre-existing central
memory cells). In the setting of newly generated T cells, LIP and
autoimmunity was clearly dependent on the presence of gc. Ourdata are consistent with studies showing that some forms of LIP are
highly dependent on lymph node stroma [2e5], and lymph nodes
are almost completely absent in Rag/ gc/ [54] recipients that
we found were protected from disease. In addition, the rules of LIP
may be different for T cells that are self antigen speciﬁc. Consistent
with this possibility a recent study showed that a self antigen
speciﬁc transgenic CD8 T cell underwent substantial LIP in gc/
but not Rag/ gc/ recipients [55]. Thus, LIP rules deﬁned by
experiments done in gc/ recipients do not necessarily hold for
studies done in completely T cell deﬁcient Rag/ gc/ recipients.
The relative lack of LIP and autoimmunity in lymph node deﬁ-
cient recipients and in neonates raises the question of how
precisely to deﬁne lymphopenia. Lymphopenia is a relative deﬁ-
ciency in lymphocytes, but relative to what exactly? For example,
the neonatal period in mice is often discussed as being a naturally
lymphopenic period relative to the adult stage. Supporting this
idea, neonates but not adults support homeostatic proliferation
[18]. However, the most relevant deﬁnition of lymphopenia might
be a low ratio of lymphocytes to available lymphoid stroma. From
this viewpoint, neonates, having both low T cell numbers and
a paucity of lymphoid stroma are not highly lymphopenic, at least
not in comparison to adult immunodeﬁcient mice. Consistent with
this view, the homeostatic proliferation seen in neonates [18]
occurs for a much smaller fraction of input T cells than when T
cells are transferred to Rag/ adult recipients [7]. Our data in
neonatal Rag/ recipients of PD-1/ HSC suggest that the T cell
repertoire that is naturally generated in a PD-1/ animal (during
the fetal/neonatal period), in the relative absence of LIP, is able to
develop sufﬁcient peripheral tolerance to prevent rapid multi-
organ autoimmunity.
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activation, a process most strong in RTE cells as revealed during
states of lymphopenia [56]. This perspective suggests a model
whereby the relatively mild autoimmunity seen in PD-1/ mice
may be explained by a partial loss in the ability to control
homeostatic activation; the restricted lymphoid environment
present in the neonatal period, when T cell homeostasis is estab-
lished, prevents a complete loss of control. As the animal grows,
and the lymphoid stroma increases, newly generated PD-1/ T
cells are controlled by the tolerant population of T cells already
present within the lymphoid tissue, a feedback mechanism.
Successful feedback may involve generation of the appropriate
balance of regulatory and effector cells [43,57] when the ﬁrst waves
of T cells seed the periphery. The natural paucity of lymphoid
stroma early in life that appears to control homeostatic activation of
PD-1 deﬁcient T cells, also raises an important question for
understanding the role of co-inhibitors. Future studies should
address how the absence of CTLA-4, but not PD-1, signaling is able
to overcome the restricted lymphoid environment of the neonatal
period to generate lethal multi-organ autoimmune disease.Acknowledgments
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